Introducing a New Insights-as-a-Service Solution for Faster, Smarter Decision-Making
SAN FRANCISCO, Sept. 30, 2015 (GLOBE NEWSWIRE) — Zephyr Health, the leading insights-as-a-service company today launched Zephyr Illuminate™, its next-generation enterprise solution for pharmaceutical, biotechnology, medical device and diagnostics companies. Zephyr Illuminate integrates global health data from thousands of disconnected sources to provide deep and actionable customer and market insights for faster, more confident decision-making across the entire product planning and launch lifecycle.
“More than 400 products will be launched in the next three years, and yet industry statistics tell us that fewer than half will achieve even half of their sales forecast. Why? Because information guiding these predictions was either wrong, incomplete or more importantly, not driven by the latest available information,” said William King, founder and CEO, Zephyr Health. “Illuminate solves long-standing issues of accessing and integrating data. This new product maximizes time to market for life sciences companies and provides market metrics to instrument their business with facts at every stage of product development, launch and commercialization.”
Illuminate brings together the core capabilities of Zephyr’s existing applications – Voyager, Cocktail and Kaleidescope – creating a next-generation insights platform with a sleek new Web and mobile interface for business users in headquarters and in the field. Illuminate’s Recommendations Engine uncovers new market and customer insights and delivers them to users via easy integration into CRM or Business Intelligence solutions. Proprietary algorithms link out-of-the-box public global healthcare data with customer and vendor data to deliver predictive analytics and actionable business insights.
“We’ve developed the world’s first all-in-one insights engine for global health data,” said Ronald Meaux, vice president of Products at Zephyr Health. “Powerful algorithms and intuitive applications make it easy for our customers to identify the best physicians and hospitals around the world for clinical research, market influence and sales potential.”
Zephyr Illuminate features include:
About Zephyr Health
Founded in 2011 by William King, Zephyr Health is the leading insights-as-a-service company harnessing the power of global health data to address critical business and patient needs. From clinical trials to market strategy and sales, Zephyr Illuminate™ helps Life Sciences companies – pharmaceutical, biotech, medical device and diagnostics – make confident decisions faster across the entire product lifecycle with precise and predictive customer and market insights. Zephyr Health’s customers include Fortune 100 biopharmaceutical, diagnostic and medical device companies Amgen, Genentech, Gilead, GSK, Medtronic, Onyx and Stryker.
Zephyr Health is a privately held company headquartered in San Francisco with offices in London, UK, and Pune, India. Zephyr Health is venture backed by Google Ventures, Kleiner Perkins Caufield & Byers and Icon Ventures. For more information, please visit: www.zephyrhealth.com.
Source: Zephyr Health
Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.
Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.
In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.